Abstract
Purpose
To analyze the quantitative and qualitative early changes of choroidal neovascularization (CNV) associated with chronic central serous chorioretinopathy (CSC) after treatment using optical coherence tomography-angiography (OCT-A).
Methods
Charts of consecutive patients with diagnosis of chronic CSC complicated by CNV were retrospectively reviewed. Included patients were divided in photodynamic therapy (PDT) or aflibercept group on the basis of the treatment received (half-fluence PDT or aflibercept 2.0 mg/0.05 ml intravitreal injection). Main outcome measures included the changes between baseline and 1-month follow-up in CNV vessel density (VD) and area on OCT-A images after thresholding and binarization.
Results
A total of 30 eyes of 26 Caucasian patients were included: 17 eyes of 15 patients in PDT group (mean age 53 ± 11 years) and 13 eyes of 11 patients in aflibercept group (mean age 58 ± 8 years [p = 0.196]). In both PDT and aflibercept groups, best-corrected visual acuity improved at 1 month, and central macular thickness and subretinal fluid significantly decreased. VD did not change after the treatment in both groups (p = 0.502 and p = 0.086) although CNV area decreased significantly (from 0.586 ± 0.449 mm2 to 0.553 ± 0.453 mm2 [0.041]) in the PDT group, and nonsignificantly (from 0.767 ± 0.466 mm2 to 0.733 ± 0.472 mm2 [p = 0.095]) in the aflibercept group. The same results were confirmed in the subanalysis of the 18 treatment-naïve eyes.
Conclusions
We demonstrated that, despite all patients showed a favorable clinical response, VD of CNVs complicating chronic CSC did not change after treatment. These findings support the idea that arteriogenesis is the main driving force of CNV in pachychoroid-related macular disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina 2013;33:1659–72.
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota,1980–2002. Ophthalmology 2008;115:169–73.
Liew G, Quin G, Gillies M, et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41:201–14.
Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–45.
Quin G, Liew G, Ho IV, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol. 2013;41:187–200.
Loo RH, Scott IU, Flynn HW Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19–24.
Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina 2015;35:1–9.
Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol. 2015;160:1243–.e2.
Carnevali A, Cicinelli MV, Capuano V, et al. Optical coherence tomography angiography: a useful tool for diagnosis of treatment-naïve quiescent choroidal neovascularization. Am J Ophthalmol. 2016;169:189–98.
Kuehlewein L, Bansal M, Lenis TL, et al. Optical coherence tomography angiography of type 1 neovascularization in age-related macular degeneration. Am J Ophthalmol. 2015;160:739–48.
Sacconi R, Baldin G, Carnevali A, et al. Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Eye 2018;32:734–42.
Sacconi R, Freund KB, Yannuzzi LA, et al. The expanded spectrum of perifoveal exudative vascular anomalous complex. Am J Ophthalmol. 2017;184:137–46.
Sacconi R, Corbelli E, Carnevali A, Querques L, Bandello F, Querques G. Optical coherence tomography angiography in geographic atrophy. Retina 2018;38:2350–5.
Carnevali A, Sacconi R, Corbelli E, et al. Optical coherence tomography angiography analysis of retinal vascular plexuses and choriocapillaris in patients with type 1 diabetes without diabetic retinopathy. Acta Diabetol. 2017;54:695–702.
Matet A, Daruich A, Dirani A, Ambresin A, Behar-Cohen F. Macular telangiectasia type 1: capillary density and microvascular abnormalities assessed by optical coherence tomography angiography. Am J Ophthalmol. 2016;167:18–30.
Demirel S, Yanık Ö, Nalcı H, Batıoğlu F, Özmert E. The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography. Graefes Arch Clin Exp Ophthalmol. 2017;255:2317–24.
Bousquet E, Bonnin S, Mrejen S, Krivosic V, Tadayoni R, Gaudric A. Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina. 2018;38:629–38.
Carnevali A, Capuano V, Sacconi R, et al. Optical coherence tomography angiography of treatment-naïve quiescent choroidal neovascularization in pachychoroid neovasculopathy. Ophthalmol Retin. 2017;1:328–32.
Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.
Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;154:366–e4.
Lumbroso B, Rispoli M, Savastano MC. Longitudinal optical coherence tomography-angiography study of type 2 naive choroidal neovascularization early response after treatment. Retina 2015;35:2242–51.
Spaide RF. Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization. Am J Ophthalmol. 2015;160:6–16.
De Carlo TE, Bonini Filho MA, Chin AT, et al. Spectral- domain optical coherence tomography angiography of choroidal neovascularization. Ophthalmology 2015;122:1228–38.
Muakkassa NW, Chin AT, de Carlo T, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina 2015;35:2252–9.
Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 2012;32:1829–37.
Demirel S, Özcan G, Yanık Ö, Batıoğlu F, Özmert E. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2019 https://doi.org/10.1007/s00417-018-04226-6.
Ma DJ, Park UC, Kim ET, Yu HG. Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy. PLoS ONE. 2018;13:e0202930.
van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 2018;125:1547–55.
Padrón-Pérez N, Arias L, Rubio M, et al. Changes in choroidal thickness after intravitreal injection of anti-vascular endothelial growth factor in pachychoroid neovasculopathy. Invest Ophthalmol Vis Sci. 2018;59:1119–24.
Acknowledgements
Financial disclosures: RS, LT, EC, AC, LQ, SC: none. FB is a consultant for Alcon (Fort Worth,Texas,USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California,USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch and Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (Évry, France), Novartis(Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee,Belgium), and Zeiss (Dublin, USA). GQ is a consultant for Amgen (Thousand Oaks, California, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Heidelberg (Germany), KHB (Shanghai, China), Novartis (Basel, Switzerland), Roche (Basel, Switzerland), Sandoz (Berlin, Germany), and Zeiss (Dublin, USA).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sacconi, R., Tomasso, L., Corbelli, E. et al. Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. Eye 33, 1809–1817 (2019). https://doi.org/10.1038/s41433-019-0511-2
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-019-0511-2
This article is cited by
-
Differences in structural optical coherence tomography and infrared enface images between non-exudative macular neovascularizations secondary to AMD and pachychoroid disease
Eye (2025)
-
Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy
Ophthalmology and Therapy (2025)
-
The spectrum of pachychoroid neovasculopathy
Graefe's Archive for Clinical and Experimental Ophthalmology (2025)
-
Long-term predictors of anti-VEGF treatment response in patients with neovascularization secondary to CSCR: a longitudinal study
Graefe's Archive for Clinical and Experimental Ophthalmology (2024)
-
Three-year outcome of photodynamic therapy combined with VEGF inhibitor for pachychoroid neovasculopathy
Graefe's Archive for Clinical and Experimental Ophthalmology (2024)
